The fact that oral semaglutide 50mg matches the injectable at 2.4mg is a significant technical achievement, but I have mixed feelings about the practical implications.

The current Rybelsus (oral sema 14mg) already has significant adherence issues because of the administration requirements:

1. Take on an empty stomach (no food for 2+ hours prior)
2. Swallow with no more than 4 oz of plain water
3. Wait at least 30 minutes before eating, drinking, or taking other meds

Those restrictions exist because SNAC only works in an empty stomach with minimal water to concentrate the local pH effect. The 50mg dose doesn't change any of that. You're still dealing with the same inconvenient administration.

Compare that to orforglipron: pop a pill, no restrictions. If I'm choosing an oral GLP-1, I know which one I'd prefer from a convenience standpoint.

I've been on Rybelsus 14mg for the past 8 months and honestly... the restrictions aren't that bad once you build a routine. I take it first thing when I wake up, brush my teeth, shower, get dressed, and by then 30+ minutes have passed and I can have breakfast.

But I know I'm only getting a fraction of the efficacy compared to injectable. If the 50mg version truly matches Wegovy-level weight loss, I'd switch in a heartbeat. The convenience of no injections is worth the morning routine to me. 💊 > 💉

Cross-trial comparison of oral vs. injectable semaglutide:

The dose-response curve is clear. And it demonstrates that oral semaglutide CAN match injectable — you just need a lot more drug to overcome the ~1% oral bioavailability. Hence 50mg oral = 2.4mg injectable (0.05 * 50mg ≈ 2.5mg absorbed).

The manufacturing cost implication is important here. Even though oral sema 50mg matches the injectable in efficacy, you're using roughly 20x more semaglutide per dose compared to the injectable. That peptide isn't cheap to synthesize.

Rybelsus 14mg is already priced similarly to Ozempic. A 50mg version would require 3.5x more API per tablet. Whether Novo can price this competitively against the injectable while eating the higher COGS is an open question.

This is fundamentally the problem with oral peptides vs. oral small molecules. Orforglipron doesn't have this inefficiency because it's not a peptide — it doesn't need an absorption enhancer and has much higher oral bioavailability. The economics favor small molecules for oral delivery.